Plain-English translation of NCT06501781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach called Peer Activate, which pairs people with a trained peer specialist to help them stick with injectable long-acting formulations of PrEP or ART (Cabotegravir-based medications). The program focuses on problem-solving, building healthier daily routines, and overcoming real-world barriers like transportation or housing—all while supporting recovery from substance use. The study compares this peer-led approach to standard medical care alone.
Injectable medications offer a major advantage for people managing HIV or taking PrEP—you don't have to remember a daily pill—but skipping doses can still happen, especially when someone is dealing with substance use or facing barriers like poverty or discrimination. This trial exists to see whether having a peer specialist help you problem-solve and build a rewarding, structured life can help you stay committed to the medication and improve your health.
You likely qualify if…
You likely don't qualify if…
You would be assigned to either receive the Peer Activate program or standard clinical care. If assigned to Peer Activate, you would meet regularly with a trained peer specialist—someone with lived experience in recovery—to work on problem-solving skills, build rewarding activities into your daily life, and address barriers to staying on your injectable medication. All participants receive access to expert HIV clinicians and support services. The study involves regular appointments and assessments to track how well the approach works.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States